Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
235
-
Total 13F shares, excl. options
-
65,481,898
-
Shares change
-
-2,364,522
-
Total reported value, excl. options
-
$6,240,143,536
-
Value change
-
-$246,149,121
-
Put/Call ratio
-
119%
-
Number of buys
-
119
-
Number of sells
-
-135
-
Price
-
$95.35
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2021
305 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2021.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 235 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65,481,898 shares
of 95,963,102 outstanding shares and own 68.24% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (10,999,214 shares), VANGUARD GROUP INC (5,666,337 shares), Capital International Investors (5,457,124 shares), Capital Research Global Investors (4,568,805 shares), FEDERATED HERMES, INC. (3,851,310 shares), BlackRock Inc. (3,491,941 shares), Capital World Investors (2,766,905 shares), Clearbridge Investments, LLC (2,370,520 shares), ALKEON CAPITAL MANAGEMENT LLC (1,913,648 shares), and CITADEL ADVISORS LLC (1,856,479 shares).
This table shows the top 235 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.